WBB Securities Analysts Begin Coverage on Stemcells Inc (STEM)
Thursday, July 07, 2021 9:30 AM

Equities research analysts at WBB Securities initiated coverage on shares of Stemcells Inc (NASDAQ: STEM) in a research note to investors on Thursday. The analysts set a "sell" rating and a $3.00 price target on the stock.

StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. The Company is focused on cellular medicine, or the use of stem and progenitor cells as the basis for therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The primary research and development efforts are focused on cellular medicine, where StemCells seeks to identify and develop stem and progenitor cells as therapeutic agents. It has two therapeutic product development programs: the CNS Program, which is developing applications for HuCNS-SC cells, the human neural stem cell product candidate, and the Liver Program, which is developing the applications for the human liver engrafting cells.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.